P. Baldi

Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.

N. Tinari, E. Ricevuto, C. Ficorella, 2012, Clinical colorectal cancer.

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

N. Tinari, E. Ricevuto, P. Marchetti, 2004, British Journal of Cancer.

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

C. Ficorella, K. Cannita, A. Parisi, 2019, Bioengineering.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis

E. Ricevuto, C. Ficorella, K. Cannita, 2017, Oncotarget.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations

E. Ricevuto, C. Ficorella, K. Cannita, 2018, Oncotarget.

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.

E. Ricevuto, C. Ficorella, K. Cannita, 2011, Oncology reports.

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

E. Ricevuto, P. Marchetti, C. Ficorella, 2010, BMC Cancer.